Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Gossamer Bio in a report released on Monday, May 19th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings of ($0.71) per share for the year, down from their previous forecast of ($0.70). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $3.95 million.
GOSS has been the subject of several other reports. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reissued an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, The Goldman Sachs Group upped their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday, May 16th.
View Our Latest Analysis on Gossamer Bio
Gossamer Bio Stock Up 8.3%
NASDAQ:GOSS opened at $1.18 on Wednesday. Gossamer Bio has a twelve month low of $0.50 and a twelve month high of $1.55. The firm has a market capitalization of $268.12 million, a price-to-earnings ratio of -3.69 and a beta of 1.82. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock's 50 day moving average price is $1.04 and its two-hundred day moving average price is $0.99.
Institutional Investors Weigh In On Gossamer Bio
Several hedge funds have recently added to or reduced their stakes in GOSS. Charles Schwab Investment Management Inc. increased its holdings in shares of Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after purchasing an additional 13,902 shares during the last quarter. Monaco Asset Management SAM boosted its holdings in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after buying an additional 1,520,721 shares during the period. Geode Capital Management LLC grew its stake in Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after buying an additional 38,084 shares during the last quarter. Smith Moore & CO. raised its holdings in Gossamer Bio by 32.7% in the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after acquiring an additional 74,000 shares during the period. Finally, Silverarc Capital Management LLC raised its holdings in Gossamer Bio by 9.3% in the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after acquiring an additional 526,495 shares during the period. Institutional investors and hedge funds own 81.23% of the company's stock.
About Gossamer Bio
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
